免疫疗法
白血病
生物
过继性细胞移植
计算生物学
免疫系统
T细胞
过继免疫治疗
癌症研究
免疫学
医学
作者
Melissa M. Berrien-Elliott,Amanda F. Cashen,Celia C. Cubitt,Carly C. Neal,Pamela Wong,Julia A. Wagner,Mark P. Foster,Timothy Schappe,Sweta Desai,Ethan McClain,Michelle Becker‐Hapak,Jennifer A. Foltz,Matthew Cooper,Natália Jaeger,Sridhar Nonavinkere Srivatsan,Feng Gao,Rizwan Romee,Camille N. Abboud,Geoffrey L. Uy,Peter Westervelt
出处
期刊:Cancer Discovery
[American Association for Cancer Research]
日期:2020-08-21
卷期号:10 (12): 1854-1871
被引量:123
标识
DOI:10.1158/2159-8290.cd-20-0312
摘要
Natural killer (NK) cells are an emerging cancer cellular therapy and potent mediators of antitumor immunity. Cytokine-induced memory-like (ML) NK cellular therapy is safe and induces remissions in patients with acute myeloid leukemia (AML). However, the dynamic changes in phenotype that occur after NK-cell transfer that affect patient outcomes remain unclear. Here, we report comprehensive multidimensional correlates from ML NK cell-treated patients with AML using mass cytometry. These data identify a unique in vivo differentiated ML NK-cell phenotype distinct from conventional NK cells. Moreover, the inhibitory receptor NKG2A is a dominant, transcriptionally induced checkpoint important for ML, but not conventional NK-cell responses to cancer. The frequency of CD8α+ donor NK cells is negatively associated with AML patient outcomes after ML NK therapy. Thus, elucidating the multidimensional dynamics of donor ML NK cells in vivo revealed critical factors important for clinical response, and new avenues to enhance NK-cell therapeutics. SIGNIFICANCE: Mass cytometry reveals an in vivo memory-like NK-cell phenotype, where NKG2A is a dominant checkpoint, and CD8α is associated with treatment failure after ML NK-cell therapy. These findings identify multiple avenues for optimizing ML NK-cell immunotherapy for cancer and define mechanisms important for ML NK-cell function.This article is highlighted in the In This Issue feature, p. 1775.
科研通智能强力驱动
Strongly Powered by AbleSci AI